Xaracoll is owned by Innocoll Pharms.
Xaracoll contains Bupivacaine Hydrochloride.
Xaracoll has a total of 1 drug patent out of which 0 drug patents have expired.
Xaracoll was authorised for market use on 28 August, 2020.
Xaracoll is available in implant;implantation dosage forms.
Xaracoll can be used as a method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours following implantation.
The generics of Xaracoll are possible to be released after 20 May, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|USRE47826||INNOCOLL PHARMS||Drug delivery device for providing local analgesia, local anesthesia or nerve blockage|| |
(5 years from now)
|New Product (NP)||Aug 28, 2023|
Drugs and Companies using BUPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 August, 2020
Treatment: A method for inducing a post-surgical analgesia sparing effect by implanting at the surgical site a collagen sponge containing bupivacaine hcl which provides local anesthesia for up to 24 hours follow...
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic